Dividend Policy & Shareholder Returns
Lantheus does not pay any dividend, and has no plans to initiate dividends in the foreseeable future (www.sec.gov) (www.sec.gov). The company has never declared a cash dividend since its inception as a public entity (www.sec.gov). Instead, management prioritizes reinvesting profits into debt reduction, growth opportunities, and share buybacks. In fact, the credit agreements limit the firm’s ability to pay dividends, reinforcing this policy (www.sec.gov) (www.sec.gov).
Rather than distribute cash via dividends, Lantheus returns capital to shareholders through stock repurchases. The Board authorized a $250 million buyback program in late 2024 (www.globenewswire.com), under which the company began repurchasing shares in Q4 2024. During 2025 Lantheus bought back approximately $300 million worth of its stock (about 6–7% of its market capitalization) including $100 million in Q4 alone (www.globenewswire.com). This was funded by the company’s strong cash flows and cash hoard accumulated from prior periods of rapid growth. Management indicated these buybacks reflect confidence in Lantheus’s leadership position in radiopharmaceuticals and its long-term growth prospects (www.globenewswire.com). The aggressive repurchase activity also suggests that, absent a dividend, buybacks are the preferred method to return excess capital to shareholders. As of early 2026, additional authorization remains (or can be refreshed) should Lantheus choose to continue opportunistic repurchases – a possibility given the stock’s recent weakness.
Given the growth-oriented strategy (with significant R&D and acquisition spend) and debt covenants inhibiting payouts, investors should not expect a dividend in the near term (www.sec.gov). Lantheus’s shareholder return strategy is likely to remain focused on buybacks if surplus cash is available, while prioritizing funding for pipeline development and potential debt retirement. Importantly, the absence of a dividend means investors rely entirely on stock price appreciation for their return (www.sec.gov) (www.sec.gov). This places a premium on execution and growth to drive the share price higher over time.
Leverage & Debt (Maturities and Coverage)
Leverage: Despite the cash outflows for acquisitions and buybacks in 2025, Lantheus’s balance sheet remains reasonably strong. Net debt is modest: at year-end 2025 the company had $568.7 million in long-term debt (virtually unchanged from $565.3 million a year prior) and only a token $0.7 million due within one year (www.globenewswire.com). Offset by $359 million cash on hand, net debt stood at roughly $210 million, a low figure relative to 2025 adjusted EBITDA and equity value. Lantheus’s net debt/EBITDA is well below 1× (implying very light leverage), which gives the company financial flexibility. Total debt equates to about 37% of total capitalization, which is not excessive for a profitable mid-cap healthcare company.
Debt composition: The vast majority of LNTH’s debt is a single issue of Convertible Senior Notes due 2027. In December 2022, Lantheus issued $575 million of 2.625% convertible notes maturing December 15, 2027 (www.sec.gov) (investor.lantheus.com). (The full $500 million offering plus a $75 million upsized allotment were placed, indicating strong demand (www.sec.gov).) These notes carry a low fixed coupon (2.625%) and are unsecured; they are convertible at a price of ~$79.81/share (130% conversion trigger ≈ $103.75) which is above the current stock price (investor.lantheus.com) (www.sec.gov). Lantheus cannot be forced to repay principal early unless certain conversion conditions are met (e.g. sustained stock price above the trigger) – indeed, in late 2024 the share price did briefly exceed the threshold, making the notes temporarily convertible at holder option (www.sec.gov), though few if any were actually converted. Barring a major sustained rally in LNTH stock, these notes will likely remain outstanding until close to maturity. The conversion feature limits dilution risk unless shares appreciate dramatically (> 60% from recent levels). Moreover, Lantheus has the right to redeem the notes for cash on or after Dec 2025 if the stock exceeds 130% of the conversion price (investor.lantheus.com) – providing an option to refinance or force conversion if conditions are favorable.
Aside from the 2027 converts, Lantheus’s only other debt consists of minor finance lease liabilities (~$1.6 million) (www.sec.gov). The company does not currently carry any term loans or senior secured debt. It maintains a revolving credit facility of up to $750 million, which is currently undrawn (www.sec.gov). In December 2024 this revolver was amended and extended; it now matures in December 2029 (www.sec.gov). The revolver provides substantial liquidity (nearly equal to Lantheus’s 2025 revenue) and can fund working capital or acquisitions if needed. At the end of 2025, the full $750 million remained available credit, giving Lantheus a combined liquidity of ~$1.1 billion (cash + revolver) to support operations and growth.
Maturity profile: Lantheus faces no significant debt maturities until late 2027, when the $575 million converts come due. The current portion of debt is essentially zero ($0.74 million) (www.globenewswire.com), indicating no scheduled term debt payments in 2026 aside from routine interest. The 2027 maturity is a single bullet payment which Lantheus will need to address by that time – either via refinancing, cash redemption, or equity conversion. Given the company’s strong cash flow and cash balance, there is a credible path to accumulate funds for repayment if necessary. Additionally, if Lantheus’s stock trades well above $80 by 2027, conversion could eliminate the debt (with some dilution). Interest rate risk is minimal, since the converts have a fixed low rate and the revolver, though floating-rate, is unused (so rising rates only impact it if drawn) (www.sec.gov). Overall, leverage risk is low – Lantheus has a manageable debt load with a comfortable timeline before maturity and ample liquidity to support its obligations.
Coverage: Lantheus’s ability to cover its debt service is very strong. Annual interest expense was ~$19.7 million in 2025 (www.globenewswire.com), which is relatively trivial against the company’s earnings and cash flow. For perspective, free cash flow in Q4 alone was $81 million (www.globenewswire.com) – over 16× the Q4 interest outlay (~$5 million) (www.globenewswire.com). On a full-year basis, interest consumed only about 5% of 2025 EBITDA (estimated) and under 6% of operating cash flow, implying an interest coverage ratio on the order of 15–20×. Even if earnings were to soften in 2026, interest payments (locked at 2.625% on the fixed notes) remain very well covered by cash generation. Additionally, Lantheus’s fixed-charge coverage is bolstered by relatively low fixed obligations (no high coupon debt, no dividend, and operating leases are modest). This financial strength has been noted by analysts – as of late 2023, Lantheus was described as “financially robust, with nearly $1 billion in cash, minimal debt, and strong operating cash flow” (seekingalpha.com). While the cash balance has since been drawn down for strategic uses, the underlying cash-generating ability of the business continues to comfortably cover all financing costs. In short, Lantheus has no trouble meeting its interest and debt commitments at present, and could even tolerate additional debt if needed (though none is planned). Maintaining this low leverage could be advantageous given the company’s pipeline investment needs, but it also provides flexibility to leverage up for an acquisition if a compelling opportunity arises.
Valuation & Peer Comparison
Stock performance: Lantheus’s stock price has undergone a significant correction over the past year. After a period of exceptional growth in 2021–2022 (driven by the launch of PYLARIFY), the shares peaked in the mid-$90s in 2023. Since then, amid flattening earnings, LNTH has pulled back to the mid-$60s per share. As of early 2026, the stock trades around $64–$68 per share (www.alphaspread.com), representing a ~26% decline from a year ago (www.alphaspread.com). Notably, a single-day drop of 24% occurred in August 2025 after Lantheus slashed its full-year guidance on disappointing Q2 results (za.investing.com). This plunge to the mid-$50s reflected investor concerns about near-term growth prospects, especially the unexpected downturn in PYLARIFY sales (za.investing.com). The stock has partly recovered from that trough, but continues to trade at a depressed valuation multiple relative to its recent history.
Earnings multiple: Based on current pricing, Lantheus’s valuation appears modest for a profitable life-sciences company – albeit justifiable by its slowing growth. Using GAAP earnings, the trailing P/E ratio is roughly 18–20× (FY 2025 GAAP EPS was $3.41 (www.globenewswire.com) and the stock is ~$65–70). However, GAAP includes large non-cash amortization charges from acquisitions; on an adjusted earnings basis (2025 Adjusted EPS $6.08 (investor.lantheus.com)), the trailing P/E is only ~11×. Even looking forward, at the midpoint of 2026 EPS guidance ($5.13), LNTH trades around 12–13× forward earnings – a relatively low multiple in the healthcare sector. For context, Lantheus’s TTM P/E was about 27× as of February 2026 (www.gurufocus.com) when using the prior trailing period that included an unusual loss in late 2024 (this elevated P/E has since normalized as one-time charges rolled off). By comparison, the broader S&P 500 trades ~18× forward earnings, and mid-cap biotech/diagnostic peers often trade 15–20× or higher when growth is healthy. Lantheus’s single-digit revenue growth (and expected 2026 earnings decline) clearly weighs on its multiple.
Relative to peers: Direct comparables to Lantheus are limited, given its unique focus on radiopharmaceutical diagnostics. However, we can consider some peer benchmarks: - Pharmaceutical diagnostics businesses (e.g. GE HealthCare’s pharmaceutical diagnostics segment, Bracco Imaging privately, or Cardinal Health’s nuclear pharmacy unit) typically grow slowly and command modest multiples, but they lack LNTH’s high-margin innovative products. - Mid-cap “theranostic” companies like Telix Pharmaceuticals (ASX: TLX), which markets a Ga-68 PSMA tracer and is developing radiotherapies, trade at rich valuations on forward potential (Telix’s market cap ~$3B despite lower current revenue than Lantheus). - Established pharma/biotech with similar revenue ($1–2B) and strong profitability often trade around 12–16× earnings, depending on growth. Lantheus, at ~12× forward, is at the low end of this range, indicating a “show me” discount due to uncertain growth.
One quantitative analysis of relative valuation (by valueinvesting.io) suggests Lantheus’s fair value could be ~$99/share if it were valued in line with industry P/E peers, implying a ~50% upside from the mid-$60s (valueinvesting.io). This underscores how cheap LNTH appears on earnings multiples – but that upside will only be realized if the company can reignite growth. The market is essentially assigning a low multiple because of concerns about PYLARIFY’s trajectory and pending patent expirations (discussed in Risks below).
Other metrics: In terms of EV/EBITDA, Lantheus also looks inexpensive. With enterprise value around $4.3B (market cap $4.4B minus net cash ~$0.2B) (www.alphaspread.com) and 2025 EBITDA (adjusted) roughly ~$500M, EV/EBITDA is in the 8–9× range. That’s well below the high-teens multiples that high-growth med-tech firms fetched when Lantheus was in hypergrowth, and closer to the multiple of a slow-growth pharma. Price/Sales is ~2.8× (based on 2025 $1.54B revenue), reasonable given ~30% historical operating margins. Overall, LNTH’s valuation reflects a company in transition: the stock no longer carries a premium growth multiple, but it could rerate higher if new products restore a growth trajectory. Conversely, if execution falters, the low multiple may not prevent further downside. In summary, Lantheus appears modestly valued relative to its earnings power – a double-edged sword signaling both potential undervaluation and the market’s skepticism about its growth outlook.
Key Risks & Red Flags
Like any mid-cap pharma/diagnostics firm, Lantheus faces several risks and potential red flags that investors should monitor:
- Reliance on Key Product (PYLARIFY): Lantheus’s fortunes are heavily tied to PYLARIFY, which contributed the majority of revenue in recent years. PYLARIFY’s growth stalled in 2025, with sales actually declining by high-single-digits due to market saturation and competition (www.globenewswire.com) (za.investing.com). The continued success of PYLARIFY is not assured – its five-year FDA exclusivity (NCE protection) expires in mid-2026, after which generic or me-too versions could emerge (www.sec.gov). Management warns that maintaining PYLARIFY’s status as the top PSMA PET agent will require differentiation on supply, service, and performance (www.sec.gov). Current competition from two Ga-68 based PSMA tracers (each marketed by rivals) has already eroded some market share (www.sec.gov). If PYLARIFY were to lose significant share or see further price erosion (e.g. from a generic entrant post-2026), Lantheus’s revenues and margins would face substantial pressure. This customer/product concentration is a major risk – few mid-cap companies are so dependent on a single product franchise.
- Pricing and Reimbursement Pressures: A key factor in PYLARIFY’s recent slowdown is pricing headwinds. In 2024, PYLARIFY’s Transitional Pass-Through (TPT) reimbursement status in the Medicare hospital outpatient setting expired (www.sec.gov). Although Medicare continued to allow separate payment for 2025 (www.sec.gov), the loss of pass-through forced discounts under the 340B program for many hospitals, compressing net realized prices. Management noted that 340B pricing resets are pressuring PYLARIFY revenue and will continue to do so into Q4 2025 (scr.zacks.com). At the same time, some large institutions constrained by budget were slower to expand PSMA PET scan volumes (za.investing.com). These reimbursement and pricing dynamics are largely outside Lantheus’s control and represent an ongoing risk. Additionally, with new products coming (e.g. Neuraceq, MK-6240), coverage by insurance and CMS will be critical. If payers decide to bundle or restrict payment for diagnostic tracers, it could dampen adoption. Pricing pressure is a notable red flag, as it can turn a growing revenue line stagnant or negative even if unit demand rises. Investors should watch for Medicare reimbursement decisions (each calendar year) and Lantheus’s gross margin trends as signs of pricing health.
- Competition & Technological Change: Competitive dynamics in radiopharmaceuticals can shift quickly. PYLARIFY’s initial first-mover advantage in PSMA PET imaging is fading as competitors (e.g. Novartis’s Locametz kit and Telix’s Illuccix, both Ga-68 PSMA tracers) aggressively market their alternatives. Lantheus is responding by launching an improved F-18 PYLARIFY formulation with a larger batch yield and more efficient manufacturing (scr.zacks.com). This new version (pending FDA approval in 1H 2026) is aimed at lowering production cost per dose and shoring up PYLARIFY’s competitive edge on supply reliability (scr.zacks.com). However, it remains to be seen if this will be enough to fully stem share loss. In other segments, Alzheimer’s diagnostics is becoming a focus for many players – e.g. Lilly’s Amyvid (F-18 amyloid tracer) is an established competitor to Neuraceq, and Lilly also launched Tauvid (first FDA-approved Tau PET tracer) which could compete with MK-6240. New blood-based biomarkers for Alzheimer’s are emerging as well; while Lantheus believes blood tests will complement rather than replace PET scans (scr.zacks.com), widespread adoption of blood screening could reduce the need for some PET imaging. Moreover, large-cap companies (GE Healthcare, Siemens etc.) could at any time invest in radiopharma diagnostics, increasing competitive pressure in Lantheus’s niche. Technological change (such as improvements in other imaging modalities or therapies that alter diagnostic workflows) also looms as a risk. For instance, if prostate cancer management evolves such that fewer diagnostic scans are required, it could shrink PYLARIFY’s addressable market. In short, Lantheus operates in a competitive and evolving field – there is no guarantee its products will remain the leaders, especially as patents expire and new innovations arrive.
- Pipeline and Acquisition Execution: Lantheus has bet heavily on its pipeline of new radiodiagnostics (and some radiotherapeutics) to drive future growth. Execution risk here is significant. The company invested over $600 million to acquire Life Molecular Imaging and Evergreen, largely for their pipeline assets (www.globenewswire.com). These pipeline bets must pay off to justify the cost. There is risk that regulatory approvals could be delayed or denied – while the Phase 3 data for MK-6240 (Tau tracer) were positive (scr.zacks.com), the FDA may scrutinize safety or manufacturing aspects of novel tracers. Similarly, LNTH-2501 (Octevy) is modeled on an existing NET imaging agent, but approval is contingent on quality and reproducibility of the new supply chain. Even if approved on schedule, market adoption is uncertain. For example, Neuraceq’s commercial uptake will depend on Alzheimer’s drug rollouts and associated reimbursement – a new therapy (Leqembi, etc.) could spur PET scan demand, but if physicians opt for simpler diagnostics or if access to PET centers is limited, usage might ramp slowly. On the therapeutic side, Lantheus’s PNT2002 and PNT2003 radiotherapy candidates (licensed from POINT Biopharma) carry typical drug development risks plus intellectual property hurdles. In fact, PNT2003’s approval is on hold pending resolution of a patent dispute with Novartis (Lutathera) (www.globenewswire.com). There is a scenario where Lantheus spends on development/trials for these assets only to face injunctions or an inability to commercialize due to IP barriers – a red flag for ROI. More broadly, integrating the acquisitions poses challenges: melding Life Molecular’s operations and Evergreen’s manufacturing into Lantheus’s culture and systems will take time, and any missteps could disrupt supply or sales. Cost overruns or delays in bringing new products to market would hurt financial performance and could squander Lantheus’s first-mover advantage in neurology diagnostics. Investors should closely watch FDA decision outcomes (the four 2026 PDUFAs) and early launch metrics of new tracers as indicators of pipeline execution success.
- Leadership Transitions and Strategy Uncertainty: Frequent C-suite changes can be a warning sign. In Lantheus’s case, there’s been notable turnover at the top. Longtime CEO Mary Anne Heino retired in 2024, and board member Brian Markison stepped in as CEO (investor.lantheus.com). However, Markison announced he would retire by end of 2025 after less than two years in the role (www.newjerseyenvironmentwire.com). As of Q1 2026, the Board is conducting a search for a new CEO, with Mary Anne Heino returning in the interim as Executive Chair and acting CEO (www.newjerseyenvironmentwire.com) (www.newjerseyenvironmentwire.com). While Heino’s steady hand is reassuring in the short term, leadership uncertainty is a risk – a permanent new CEO’s vision may lead to shifts in strategy or priorities. Any strategic missteps during this transition (or a protracted search for new leadership) could hinder Lantheus’s ability to execute in this crucial period of multiple product launches. Moreover, the very decision to pivot away from therapeutics (seeking “value-maximizing alternatives” for them (www.globenewswire.com)) suggests management recognized it may not have the bandwidth to develop and market both diagnostics and therapies. This raises questions – will Lantheus spin off or sell its therapeutic pipeline, and if so, can it obtain good value? A poorly executed divestiture could leave value on the table. On the other hand, if it retains those assets without full commitment, that could drain resources. Thus, strategic direction risk is present. Investors should monitor communications from the new CEO (once appointed) for clarity on whether Lantheus will remain a pure-play diagnostics firm or re-expand into therapeutics under different leadership.
- Financial & Other Risks: Additional standard risks include regulatory/compliance issues (radiopharmaceuticals are highly regulated by FDA, NRC, etc. – any manufacturing or safety non-compliance could disrupt operations), supply chain dependency (PET isotopes like F-18 have short half-lives; any production outages at partner sites could halt product availability), and legal liabilities (product liability or environmental claims related to radioactive materials). The company’s concentrated manufacturing network means any given PET facility outage can impact regional sales. Lantheus also licenses key intellectual property (e.g. it licenses the PYLARIFY compound from Johns Hopkins); losing a license or a patent challenge could be detrimental (investor.lantheus.com). Lastly, market volatility and macro conditions can affect Lantheus – for instance, hospital staffing or budget constraints post-pandemic have been cited as factors in imaging volume trends (za.investing.com). While Lantheus cannot control these external factors, they pose risk to meeting growth expectations.
In sum, Lantheus’s risk profile has increased compared to its high-growth phase a couple of years ago. The slowdown of PYLARIFY is a central red flag, and it puts pressure on the company to execute perfectly on new launches. The silver lining is that Lantheus is aware of these challenges – evidenced by proactive steps like improving PYLARIFY’s formulation (scr.zacks.com), acquiring complementary products, and refocusing the business. Still, investors should approach with caution: the next 12–18 months carry pivotal risks that could significantly sway Lantheus’s trajectory.
Outlook & Open Questions
Lantheus stands at a crossroads in 2026, with multiple opportunities on the horizon but also uncertainties. Here are key open questions and considerations about the company’s outlook:
- Can new products offset the PYLARIFY decline? Lantheus is banking on its next-generation diagnostic agents (Neuraceq, Octevy, MK-6240, etc.) to reignite growth. An open question is how quickly and robustly these new radiodiagnostics will be adopted. For example, will Alzheimer’s specialists embrace PET scanning (Neuraceq/MK-6240) now that disease-modifying treatments are available? Early signs are positive – Lantheus reports that Neuraceq is now the second-largest amyloid PET agent in the U.S. and rapidly growing (www.globenewswire.com). They are expanding production sites to meet demand (20 manufacturing facilities online, 6 more planned) (scr.zacks.com). However, it remains to be seen if this translates into hundreds of millions in revenue over the next few years. Similarly, Octevy (Ga-68 edotreotide) will target a niche (neuroendocrine tumor imaging) – valuable, but likely a smaller market than PYLARIFY. The big unknown is whether aggregate growth from new products will outweigh the projected ~$100+ million decline in PYLARIFY sales in 2026. Management’s 2026 guidance (revenue down ~6%-9%) suggests they anticipate not fully offsetting Pylarify’s dip next year (www.globenewswire.com). But beyond 2026, if PYLARIFY stabilizes (helped by the new formulation and returning customers (scr.zacks.com)) and new tracers ramp up, could Lantheus resume a growth trajectory? The answer will hinge on execution in product launches and the overall demand in these diagnostic markets.
- What will become of Lantheus’s radiotherapeutic programs? The company’s decision to sharpen focus on diagnostics implies the radiotherapy assets (PNT2002 & PNT2003) may be spun-off, partnered, or sold (www.globenewswire.com). This raises questions: Is Lantheus effectively exiting the therapeutic business? If so, how will it monetize those programs? One clue: PNT2003 (targeting neuroendocrine tumors) is on hold due to Novartis’s IP – perhaps Lantheus might wait until Lutathera’s exclusivity expires in 2026–2027 (scr.zacks.com), then proceed. PNT2002 (a prostate cancer therapeutic) is potentially high-value given the success of Novartis’s Pluvicto (a similar Lu-177 PSMA therapy). Notably, POINT Biopharma (the originator) was acquired by Eli Lilly in late 2023 – but Lantheus retains commercial rights to PNT2002/2003 via its 2022 licensing deal (investor.lantheus.com). Lilly could be a logical buyer or partner if Lantheus steps back from commercialization. Will Lantheus cut a deal with Lilly or another pharma? A sale could bring in a substantial one-time cash inflow (helping replenish the war chest), but losing the upside of those therapies. Alternatively, Lantheus might form a joint venture or simply let the programs progress until ready to launch, then assign them to a partner for marketing. The company has not yet announced specifics, making this an open question that investors are keenly watching. It speaks to the strategic identity of Lantheus: pure diagnostics or a broader theranostics player? The outcome will shape the company’s growth profile (diagnostics generally smaller, quicker sales; therapeutics larger, but riskier).
- How will the leadership transition be resolved, and what strategy will the new CEO pursue? With CEO Brian Markison retiring effective Dec 31, 2025 and a search underway for the next chief executive (www.newjerseyenvironmentwire.com), Lantheus’s leadership will likely change in 2026. Mary Anne Heino’s return as interim CEO/Executive Chair provides continuity (www.newjerseyenvironmentwire.com) (www.newjerseyenvironmentwire.com), but a permanent outsider could arrive with new ideas. Key questions include: Will the new CEO maintain the current strategy of focusing on diagnostics and organic pipeline growth, or could they consider more transformational moves (e.g. M&A or even a sale of the company)? Given Lantheus’s unique position, it could be an attractive acquisition target for larger healthcare companies wanting a radiopharma platform. If the stock remains undervalued, this possibility grows – though no indications of takeover talks are public. Conversely, a new CEO might double down on Lantheus’s independence and invest aggressively in R&D, potentially even revisiting radiotherapeutics if the market evolves. Until a successor is named and articulates their vision, there is uncertainty around Lantheus’s long-term game plan. Investors will be watching the appointment closely, as leadership will be crucial in navigating the competitive and regulatory challenges ahead.
- Will macro and healthcare trends support Lantheus’s growth? On a higher level, Lantheus’s growth depends on trends in healthcare: adoption of precision diagnostics, reimbursement climate, and patient access. Open questions here include: Will Medicare and insurers continue to cover high-tech diagnostics like PET scans for Alzheimer’s on a broad basis? (Early signs are yes – CMS has expanded coverage alongside new AD drugs, which bodes well for Neuraceq and MK-6240.) Can Lantheus expand globally – e.g. PYLARIFY in international markets? (They recently partnered with GE Healthcare to seek approval in Japan (scr.zacks.com), pointing to growth avenues abroad). Also, how might emerging technologies (AI imaging analysis, new biomarkers) complement or compete with Lantheus’s products? The company is already dabbling in AI with its aPROMISE/PSMA AI software (www.sec.gov), aiming to enhance the utility of scans. The overarching question: Is nuclear medicine entering a golden age of growth (with Lantheus at the forefront), or will its use remain limited to niche areas? The answer will unfold over the coming years as we see how demand for diagnostic imaging evolves, especially in oncology and neurology.
In conclusion, Lantheus’s near-term results (2025–2026) may see turbulence, but the longer-term opportunities in its pipeline are substantial if executed well. Investors should keep an eye on the upcoming FDA approval decisions (Q1–Q3 2026) and initial adoption curves of new products for evidence that “the next chapter” of growth is materializing. If Lantheus can stabilize PYLARIFY’s decline and successfully ramp its neuro and oncology diagnostic franchises, it could resume a strong growth trajectory – potentially rewarding the patience of those buying in at today’s valuation. However, if hurdles emerge (regulatory setbacks, weak launches, etc.), the company’s pivot may take longer than hoped. 2026 will be an “acid test” year that answers many of these open questions. As the Q4 2025 report title suggests, key business insights await – and by the end of 2026, we should know whether Lantheus has navigated its challenges and unlocked a new phase of value creation or if further course-corrections are needed. Investors and analysts alike will be watching closely, data by data, catalyst by catalyst, as Lantheus’s story continues to unfold. (www.globenewswire.com) (scr.zacks.com)
